NRx Pharmaceuticals, Inc.
NRX-100
treatment-resistant depression with suicidality
Countdown
177days
FDA decision · ~ Dec 31, 2026 estimated
What's at stake
The FDA's approval decision on NRX-100 for treatment-resistant depression with suicidality is due ~ Dec 31, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 14h ago
“NRx anticipates submitting the New Drug Application in Q2 aiming for a 2026 PDUFA date.”